Drug developer AtheroGenics (AGIX) said Wednesday its failed heart-drug candidate showed signs it may be effective as an oral anti-diabetic drug
The company is currently recruiting patients for a Phase III clinical trial on the drug candidate
Wall St. seemed to think that the news put any recovery at the company almost out of reach. Its shares dropped 19% to $2.44. They have a 52-week high of $15.70.
Douglas A. McIntyre
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
